Metformin 500 mg Reviews: UKPDS Events, Not Weight-Loss Cart

What UKPDS 34 counted

Start with the paper, not with a guideline slogan. The slogan came after the counts.

UKPDS 34, Lancet 1998, sat inside a larger British program that followed newly diagnosed type 2 diabetes. The metformin question used overweight patients - more than 120 percent of ideal body weight. Of 1,704 such people, 753 entered the randomised comparison: 342 to intensive policy with metformin, 411 to conventional policy built mainly on diet. Median follow-up 10.7 years. Median HbA1c landed at 7.4 percent on metformin versus 8.0 percent on conventional care. That is a real glucose gap. It is not the line that moved the field. A 0.6-point A1c difference does not, by itself, explain a first-line habit that outlasted a dozen newer orals.

Versus conventional policy, metformin cut any diabetes-related endpoint by 32 percent, diabetes-related death by 42 percent, all-cause mortality by 36 percent, and myocardial infarction by 39 percent. Those are the numbers I file when someone says 'it only lowers sugar.' Plenty of tablets move HbA1c. Far fewer, in a randomised setting of that era, moved deaths and heart attacks. A secondary look against overweight people on intensive sulphonylurea or insulin also favoured metformin on several aggregates, including all-cause mortality and stroke. That is why a 500 mg start still opens so many first scripts. Reviews that never name those endpoints are not reviews. They are price lists.

What the design will not carry

Strike the overclaim. Benefit came from an overweight subgroup of a larger program, not from a modern placebo-controlled cardiovascular outcomes trial built only to re-prove metformin. You could not ethically withhold an established first-line tablet today to rerun that experiment. Sample sizes look small next to contemporary CVOTs. The conventional arm was diet-first, not a slick active comparator. Those limits are real. They do not erase the signal. They stop you from talking as if every person on a 500 mg chip has a personalised 42 percent death reduction stamped on the bottle. A review that quotes the 42 percent and hides the overweight frame is doing marketing.

There is a second wrinkle I will not hide. A supplementary randomisation added metformin early onto maximum sulphonylurea and saw more diabetes-related death in that small add-on group. Combined analyses and later epidemiologic looks did not confirm a class-wide poison story, and practice did not abandon the combination. Still: the paper is not a cartoon of unbroken benefit. File the main overweight comparison as the reason metformin outranked old orals. File the add-on caution as a reminder that trial appendices exist. Honesty about a 1998 appendix is part of why this desk still trusts the main result.

Not a weight-loss cart

The other claim on this slug is a cart: take 500 mg, watch the scale, skip the harder drugs.

Metformin is weight-neutral or mildly down. Some people lose a few kilograms, partly because early gut effects blunt appetite. That is not an obesity indication. The US label is type 2 diabetes as an adjunct to diet and exercise. Reviews that treat a 500 mg tablet like a GLP-1 injector are selling a different product. Dedicated weight-loss medicines move the scale in a range metformin never claimed and never showed. A friend who 'dropped a stone on Glucophage' may have dropped water, meals, and a few kilos of gut-driven appetite loss. That anecdote is not a trial endpoint.

Why the confusion lasts: first-line diabetes care and weight sit in the same clinic visit, and metformin does not cause the gain that sulphonylureas and insulin often do. 'Does not make you heavier' is a genuine advantage. 'Is a weight-loss cart' is a strike. If weight is the primary goal without diabetes or a related metabolic brief, this is the wrong file. If diabetes is the brief, the 500 mg start is still a foundation, not a substitute for the agents that now carry dedicated heart-failure, kidney, and weight trial programs. Keep the chip. Do not ask it to be a weekly pen.

Prediabetes: the DPP ranks it second

The Diabetes Prevention Program is the second-strongest named trial on this board. People with prediabetes - high sugar, not yet diabetes - were randomised to intensive lifestyle, metformin, or placebo. Both active arms cut progression. Lifestyle cut it by about 58 percent. Metformin cut it by about 31 percent. Diet and exercise won. Long follow-up kept a benefit in view for years. That ranking is why guidelines put lifestyle first and reserve metformin for groups where the drug's effect was strongest - often younger people, higher BMI, prior gestational diabetes. A 500 mg prevention script that never mentions walking is a cart with a different label glued on.

File the honest sentence: metformin can delay diabetes. It does not buy anyone out of the work the lifestyle arm won on. Starting doses for that use still look like the labeled 500 mg climb, which belongs in the titration and eGFR walkthrough. Do not let a prevention script become a permission slip to ignore meals and walking. If the numbers are already in the diabetes range, this is no longer a DPP conversation. It is a type 2 start, and UKPDS 34 is the named file again.

PCOS is a side file, not the headline

Polycystic ovary syndrome is off-label territory with mixed trials. Insulin resistance is part of many PCOS pictures, so improving insulin sensitivity has a rationale. Metformin can help menstrual regularity, ovulation, and metabolic markers, especially when glucose handling is already impaired. That overlap is real. It is also narrower than early enthusiasm suggested.

For fertility alone, dedicated ovulation-induction drugs generally work better; metformin is no longer first-line fertility treatment by itself. For acne and excess hair, the effect is modest at best. Honest framing: a limited metabolic tool inside a syndrome, strongest where insulin resistance and glucose problems dominate. Not a cure for every feature. A clinician who follows current PCOS guidance should weigh it, not a cart review.

Newer agents layer on; they do not retire the 500 mg start

The last claim: SGLT2 inhibitors and GLP-1 agonists made metformin obsolete. Open the clinic, not the ad.

Two things still separate classes: hypoglycaemia when used alone, and weight. Metformin scores well on both, which is why it remains a foundation even as newer drugs stack on top. Sulphonylureas are cheap and effective but push insulin release, so lows and gain follow. SGLT2 inhibitors and GLP-1 receptor agonists avoid hypoglycaemia when used alone, tend to reduce weight, and have cardiovascular and kidney benefits in dedicated modern trials. Those benefits are stronger and cleaner than UKPDS 34 on those organs. Cost and route differ: metformin is a cheap tablet; many GLP-1 agonists are expensive and injected.

Practical file: start metformin; if control is short, or if heart failure, atherosclerotic disease, or kidney disease is already on the chart, add the newer class for the organ protection UKPDS was never built to isolate. Layering, not a replacement contest. Side-effect and eGFR rules that shape the metformin half of that stack are in the titration and eGFR walkthrough. How the molecule got from a weed to a chip is in the plant-to-pill file.